Akari Therapeutics (AKTX)

Akari Therapeutics (AKTX) Stock Price & Analysis


AKTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.19 - $1.61
Previous Close$0.19
Average Volume (3M)163.37K
Market Cap
Enterprise Value$9.34M
Total Cash (Recent Filing)$8.15M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.5
Jun 01, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding74,449,171
10 Day Avg. Volume146,442
30 Day Avg. Volume163,374
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)2.29
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.51
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $0.18 and its highest was $1.61 in the past 12 months.
    What is Akari Therapeutics’s market cap?
    Currently, no data Available
    When is Akari Therapeutics’s upcoming earnings report date?
    Akari Therapeutics’s upcoming earnings report date is Jun 01, 2023 which is in 64 days.
      How were Akari Therapeutics’s earnings last quarter?
      Currently, no data Available
      Is Akari Therapeutics overvalued?
      According to Wall Street analysts Akari Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Akari Therapeutics pay dividends?
        Akari Therapeutics does not currently pay dividends.
        What is Akari Therapeutics’s EPS estimate?
        Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Akari Therapeutics have?
        Akari Therapeutics has 74,449,170 shares outstanding.
          What happened to Akari Therapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Akari Therapeutics?
          Currently, no hedge funds are holding shares in AKTX


          Akari Therapeutics Stock Smart Score

          This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
          Learn more about TipRanks Smart Score

          Company Description

          Akari Therapeutics

          Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.


          Forecast EPS vs Actual EPS

          Currently, no data available
          Please return soon. This page is being updated.

          Similar Stocks
          Price & Change
          Elite Pharmaceuticals
          Cumberland Pharmaceuticals
          Item 9 Labs

          Popular Stocks

          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis